Thomas Reinert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9496263/publications.pdf

Version: 2024-02-01

24	3,861	430874	642732
papers	citations	18 h-index	23 g-index

24	24	24	6089
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Direct detection of early-stage cancers using circulating tumor DNA. Science Translational Medicine, 2017, 9, .	12.4	808
2	Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncology, 2019, 5, 1124.	7.1	538
3	Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell, 2016, 30, 27-42.	16.8	486
4	Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut, 2016, 65, 625-634.	12.1	381
5	Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. Journal of Clinical Oncology, 2019, 37, 1547-1557.	1.6	298
6	Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer. Clinical Cancer Research, 2017, 23, 5437-5445.	7.0	232
7	Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers. Clinical Cancer Research, 2011, 17, 5582-5592.	7.0	183
8	Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. European Urology, 2016, 70, 75-82.	1.9	174
9	Mutational Context and Diverse Clonal Development in Early and Late Bladder Cancer. Cell Reports, 2014, 7, 1649-1663.	6.4	128
10	Diagnosis of Bladder Cancer Recurrence Based on Urinary Levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 Hypermethylation. PLoS ONE, 2012, 7, e46297.	2.5	112
11	Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. Clinical Cancer Research, 2022, 28, 507-517.	7.0	104
12	The effect of surgical trauma on circulating free DNA levels in cancer patientsâ€"implications for studies of circulating tumor DNA. Molecular Oncology, 2020, 14, 1670-1679.	4.6	89
13	Prognostic Impact of a 12-gene Progression Score in Nonâ€"muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. European Urology, 2017, 72, 461-469.	1.9	74
14	Multicenter Validation of Cyclin D1, MCM7, TRIM29, and UBE2C as Prognostic Protein Markers in Non-Muscleâ€"Invasive Bladder Cancer. American Journal of Pathology, 2013, 182, 339-349.	3.8	71
15	Combinations of Urinary Biomarkers for Surveillance of Patients with Incident Nonmuscle Invasive Bladder Cancer: The European FP7 UROMOL Project. Journal of Urology, 2013, 189, 1945-1951.	0.4	48
16	Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study. European Journal of Cancer, 2022, 163, 163-176.	2.8	33
17	Methylation Markers for Urine-Based Detection of Bladder Cancer: The Next Generation of Urinary Markers for Diagnosis and Surveillance of Bladder Cancer. Advances in Urology, 2012, 2012, 1-11.	1.3	29
18	Circulating tumor <scp>DNA</scp> for prognosis assessment and postoperative management after curativeâ€intent resection of colorectal liver metastases. International Journal of Cancer, 2022, 150, 1537-1548.	5.1	22

#	Article	IF	Citations
19	Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients.. Journal of Clinical Oncology, 2021, 39, 11-11.	1.6	18
20	Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC.. Journal of Clinical Oncology, 2020, 38, 4009-4009.	1.6	10
21	Ageâ€stratified reference intervals unlock the clinical potential of circulating cellâ€free <scp>DNA</scp> as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer. International Journal of Cancer, 2021, 148, 1665-1675.	5.1	9
22	Error Characterization and Statistical Modeling Improves Circulating Tumor DNA Detection by Droplet Digital PCR. Clinical Chemistry, 2022, 68, 657-667.	3.2	9
23	Serial circulating tumor DNA analysis to assess recurrence risk, benefit of adjuvant therapy, growth rate and early relapse detection in stage III colorectal cancer patients.. Journal of Clinical Oncology, 2021, 39, 3540-3540.	1.6	5
24	Plasma-only ctDNA-Guided MRD Detection in Patients with CRCâ€”Letter. Clinical Cancer Research, 2021, 27, 6613-6613.	7.0	0